Omentum provides a special cell microenvironment for ovarian cancer.
adipocyte
exercise
metformin
omentum
ovarian cancer
Journal
Cancer reports (Hoboken, N.J.)
ISSN: 2573-8348
Titre abrégé: Cancer Rep (Hoboken)
Pays: United States
ID NLM: 101747728
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
revised:
18
06
2023
received:
06
05
2023
accepted:
25
06
2023
medline:
27
10
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
ppublish
Résumé
Ovarian cancer seriously threatens women's health because of its poor prognosis and high mortality. Due to the lack of efficient early detection and screening methods, when patients seek doctors' help with complaints of abdominal distension, back pain and other nonspecific signs, the clinical results always hint at the widespread metastasis of disease. When referring to the metastasis of this disease, the omentum always takes precedence. The distinguishing feature of the omentum is adipose tissue, which satisfies the energy demand of cancer cells and supplies a more aggressive environment for ovarian cancer cells. In this review, we mainly focus on three important cell types: adipocytes, macrophages, and mesenchymal stem cells. Besides, several mechanisms underlying cancer-associated adipocytes (CAA)-facilitated ovarian cancer cell development have been revealed, including their capacities for storing lipids and endocrine function, and the release of hormones, growth factors, and adipokines. Blocking the reciprocity among cancer cells and various cells located on the omentum might contribute to ovarian cancer therapy. The inhibition of hormones, growth factors and adipokines produced by adipocytes will be a novel therapeutic strategy. However, a sufficient number of trials has not been performed. In spite of this, the therapeutic potential of metformin and the roles of exercise in ovarian cancer will be worth mentioning. It is almost impossible to overcome completely ovarian cancer at the moment. What we can do is trying our best to improve these patients' prognoses. In this process, adipocytes may bring promising future for the therapy of ovarian cancer.
Sections du résumé
BACKGROUND
Ovarian cancer seriously threatens women's health because of its poor prognosis and high mortality. Due to the lack of efficient early detection and screening methods, when patients seek doctors' help with complaints of abdominal distension, back pain and other nonspecific signs, the clinical results always hint at the widespread metastasis of disease. When referring to the metastasis of this disease, the omentum always takes precedence.
RECENT FINDINGS
The distinguishing feature of the omentum is adipose tissue, which satisfies the energy demand of cancer cells and supplies a more aggressive environment for ovarian cancer cells. In this review, we mainly focus on three important cell types: adipocytes, macrophages, and mesenchymal stem cells. Besides, several mechanisms underlying cancer-associated adipocytes (CAA)-facilitated ovarian cancer cell development have been revealed, including their capacities for storing lipids and endocrine function, and the release of hormones, growth factors, and adipokines. Blocking the reciprocity among cancer cells and various cells located on the omentum might contribute to ovarian cancer therapy. The inhibition of hormones, growth factors and adipokines produced by adipocytes will be a novel therapeutic strategy. However, a sufficient number of trials has not been performed. In spite of this, the therapeutic potential of metformin and the roles of exercise in ovarian cancer will be worth mentioning.
CONCLUSION
It is almost impossible to overcome completely ovarian cancer at the moment. What we can do is trying our best to improve these patients' prognoses. In this process, adipocytes may bring promising future for the therapy of ovarian cancer.
Identifiants
pubmed: 37605299
doi: 10.1002/cnr2.1858
pmc: PMC10598246
doi:
Substances chimiques
Adipokines
0
Hormones
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1858Informations de copyright
© 2023 The Authors. Cancer Reports published by Wiley Periodicals LLC.
Références
Cell Transplant. 2021 Jan-Dec;30:9636897211027819
pubmed: 34238029
Oncogene. 2020 Feb;39(8):1681-1695
pubmed: 31705064
Cancer Cell. 2016 Aug 8;30(2):273-289
pubmed: 27478041
Nature. 2007 Jun 21;447(7147):959-65
pubmed: 17554340
Oncotarget. 2018 May 18;9(38):25115-25126
pubmed: 29861857
Endocr Relat Cancer. 2012 Apr 10;19(2):197-208
pubmed: 22277193
J Exp Med. 2020 Apr 6;217(4):
pubmed: 31951251
Cancer Res. 2020 Apr 15;80(8):1748-1761
pubmed: 32054768
Int J Cancer. 2014 Jan 1;134(1):32-42
pubmed: 23784932
Cancer Res. 2020 Mar 1;80(5):1156-1170
pubmed: 31932454
Nat Rev Drug Discov. 2008 Jun;7(6):489-503
pubmed: 18511927
J Immunol. 2000 Jan 15;164(2):733-8
pubmed: 10623817
Cancer. 2006 Feb 1;106(3):599-608
pubmed: 16388521
Biochimie. 2004 Nov;86(11):839-48
pubmed: 15589694
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32369446
Stem Cells Int. 2019 Oct 20;2019:9037197
pubmed: 31781249
J Cell Biochem. 2018 Feb;119(2):2333-2344
pubmed: 28885729
J Cell Mol Med. 2021 May;25(9):4434-4443
pubmed: 33830648
Am J Pathol. 2013 Aug;183(2):576-91
pubmed: 23885715
Nat Commun. 2016 Mar 29;7:11150
pubmed: 27021436
Apoptosis. 2017 Apr;22(4):558-569
pubmed: 28012060
Adv Anat Pathol. 2019 Jan;26(1):69-74
pubmed: 30339548
Commun Biol. 2020 Sep 22;3(1):524
pubmed: 32963283
Mol Oncol. 2021 Mar;15(3):790-800
pubmed: 32741068
Cells. 2021 Aug 18;10(8):
pubmed: 34440886
Anticancer Res. 2009 Dec;29(12):5229-34
pubmed: 20044641
Int J Mol Sci. 2019 May 22;20(10):
pubmed: 31121868
Lancet Oncol. 2008 Aug;9(8):808
pubmed: 18672217
Cancers (Basel). 2016 Aug 26;8(9):
pubmed: 27571105
CA Cancer J Clin. 2018 Jul;68(4):284-296
pubmed: 29809280
Proc Natl Acad Sci U S A. 2018 Aug 14;115(33):8370-8375
pubmed: 30061407
Onco Targets Ther. 2021 Jan 12;14:325-336
pubmed: 33469309
Cancer Metastasis Rev. 1989 Aug;8(2):98-101
pubmed: 2673568
Clin Cancer Res. 2014 Jun 15;20(12):3280-8
pubmed: 24756370
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Carcinogenesis. 2011 Apr;32(4):589-96
pubmed: 21173433
Genes Nutr. 2010 Jun;5(2):121-8
pubmed: 19847467
Carcinogenesis. 2020 Apr 22;41(2):182-193
pubmed: 31046126
PLoS One. 2013 Dec 02;8(12):e81859
pubmed: 24312594
Cancers (Basel). 2020 Sep 30;12(10):
pubmed: 33008042
Mol Oncol. 2022 Jul;16(13):2558-2574
pubmed: 35278271
Nat Commun. 2018 Jul 26;9(1):2923
pubmed: 30050129
Int J Oncol. 2013 Mar;42(3):1113-9
pubmed: 23354006
Anat Embryol (Berl). 2005 Feb;209(3):251-61
pubmed: 15662530
Endokrynol Pol. 2019;70(1):57-63
pubmed: 30450532
Am J Pathol. 2016 Apr;186(4):733-47
pubmed: 27012190
Cancer Immunol Immunother. 2020 Jan;69(1):115-126
pubmed: 31802182
Int J Mol Sci. 2020 Feb 12;21(4):
pubmed: 32059381
Front Endocrinol (Lausanne). 2022 Oct 06;13:1018515
pubmed: 36277714
Cancer Res. 2015 Dec 1;75(23):5046-57
pubmed: 26573796
Immunity. 2014 Feb 20;40(2):274-88
pubmed: 24530056
Sci Rep. 2016 Dec 08;6:38498
pubmed: 27929108
Proc Nutr Soc. 2012 Feb;71(1):181-9
pubmed: 22051112
Cancer Rep (Hoboken). 2023 Oct;6(10):e1858
pubmed: 37605299
Exp Cell Res. 2015 Sep 10;337(1):16-27
pubmed: 26209607
FEBS J. 2012 Aug;279(15):2610-23
pubmed: 22621751
Int J Mol Sci. 2013 May 07;14(5):9751-66
pubmed: 23652833
Oncotarget. 2014 Jul 15;5(13):4746-64
pubmed: 24970804
Bioorg Med Chem Lett. 2007 Jun 15;17(12):3511-5
pubmed: 17502136
Clin Immunol. 2009 Nov;133(2):157-70
pubmed: 19740705
Biomedicines. 2022 Apr 16;10(4):
pubmed: 35453670
Oncogene. 2017 Feb 16;36(7):912-921
pubmed: 27568980
Aging (Albany NY). 2021 Aug 5;13(15):19750-19759
pubmed: 34351305
Gynecol Oncol. 2020 Sep;158(3):803-811
pubmed: 32616402
Mol Cell Endocrinol. 2010 Mar 25;316(2):129-39
pubmed: 19723556
Oncol Lett. 2019 Jul;18(1):561-570
pubmed: 31289528
Am J Cancer Res. 2021 Oct 15;11(10):5045-5062
pubmed: 34765311
Eur Rev Med Pharmacol Sci. 2019 May;23(10):4149-4155
pubmed: 31173285
J Clin Invest. 2019 Jul 2;129(8):3006-3017
pubmed: 31264969
Cell Death Dis. 2020 Jan 13;11(1):25
pubmed: 31932581
Oncogene. 2018 Apr;37(17):2285-2301
pubmed: 29398710